Relistor (methylnaltrexone bromide) is a small molecule pharmaceutical. Methylnaltrexone bromide was first approved as Relistor on 2008-04-24. It is used to treat constipation in the USA. It has been approved in Europe to treat constipation and opioid-related disorders. The pharmaceutical is active against mu-type opioid receptor. In addition, it is known to target delta-type opioid receptor and kappa-type opioid receptor. Relistor's patents are valid until 2031-03-10 (FDA).
|Common Name||Methylnaltrexone bromide|
|Indication||constipation, opioid-related disorders|
|Drug Class||Narcotic agonists/antagonists (normorphine type)|